Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ACAD stock hub

ACADIA Pharmaceuticals Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ACADis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ACAD

In the news

Latest news · ACAD

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E42.7

P25 12.3P50 18.4P75 33.1

Trailing P/E10.2

P25 14.9P50 23.2P75 38.5

ROE37.3

P25 -105.6P50 -46.5P75 -3.1

ROIC17.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ACAD market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

246

Groups with data

Currency

USD

Showing 246 of 246 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001070494
Company name	ACADIA Pharmaceuticals Inc.
Country	United States
Country code	US
Cusip	004225108
Employees	798
Employees Change	144%
Employees Change Percent	22.02
Enterprise value	$3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2004-05-27
Isin	US0042251084
Last refreshed	2026-05-10
Market cap	$3.8B
Market cap category	Mid-Cap
Price	$22.4
Price currency	USD
Rev Per Employee	1,372,493.73x
Sector	Healthcare
Sic	2834
Symbol	ACAD
Website	https://www.acadia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	9.79%
EV Earnings	8.08x
EV Sales Forward	3.08x
EV/EBIT	37.51x
EV/EBITDA	32.74x
EV/FCF	26.72x
EV/Sales	2.77x
FCF yield	2.96%
Forward P/E	42.73x
P/B ratio	3.07x
P/E ratio	10.2x
P/S ratio	3.5x
PE Ratio3 Y	23.12x
PS Forward	3.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	7.39%
EBITDA Margin	8.46%
FCF margin	10.37%
Gross margin	61.58%
Gross Profit	$674.4M
Gross Profit Growth	13.32%
Gross Profit Growth Q	14.24%
Gross Profit Growth3 Y	47.66%
Gross Profit Growth5 Y	29.21%
Net Income	$375.7M
Net Income Growth	64.12%
Net Income Growth Q	-80.85%
Net Income Growth Years	3%
Pretax Margin	10.51%
Profit Margin	34.3%
Profit Per Employee	$470,739
Profitable Years	2
ROA	3.69
Roa5y	-6.55
ROCE	6.22
ROE	37.32
Roe5y	-2.12
ROIC	17.83
Roic5y	-106.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-2.08%
Cagr15y	16.12%
Cagr1y	51.29%
Cagr20y	3.16%
Cagr3y	0.71%
Cagr5y	1.23%
EPS Growth	60.43
EPS Growth Q	-81.82
EPS Growth Years	3
FCF Growth	-23.48%
FCF Growth Q	41.56%
OCF Growth	-17.1%
OCF Growth Q	67.21%
Revenue Growth	9.93x
Revenue Growth Q	9.72x
Revenue Growth Quarters	14x
Revenue Growth Years	10x
Revenue Growth3 Y	28.17x
Revenue Growth5 Y	19.04x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.8
Assets	$1.6B
Cash	$851.5M
Current Assets	$1.1B
Current Liabilities	$305.5M
Debt	$50.8M
Debt EBITDA	$0.48
Debt Equity	$0.04
Debt FCF	$0.45
Equity	$1.2B
Liabilities	$357.2M
Long Term Assets	$509.2M
Long Term Liabilities	$51.6M
Net Cash	$800.7M
Net Cash By Market Cap	$20.87
Net Cash Growth	27.99%
Net Debt EBITDA	$-8.64
Net Debt Equity	$-0.64
Net Debt FCF	$-7.05
Tangible Book Value	$1.1B
Tangible Book Value Per Share	$6.67
WACC	8.86

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.59
Inventory Turnover	15.44
Net Working Capital	$-49.2M
Quick ratio	3.27
Working Capital	$790.5M
Working Capital Turnover	$1.61

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.73%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-18.99%
1Y total return	51.25%
200-day SMA	23.74
3Y total return	2.14%
50-day SMA	21.95
50-day SMA vs 200-day SMA	50under200
5Y total return	6.31%
All Time High	58.72
All Time High Change	-61.85%
All Time High Date	2020-07-07
All Time Low	0.65
All Time Low Change	3,346.15%
All Time Low Date	2010-11-12
ATR	0.8
Beta	0.86
Beta1y	1.7
Beta2y	1.13
Ch YTD	-16.14
High	22.91
High52	28.35
High52 Date	2025-12-23
High52ch	-20.99%
Low	22.26
Low52	14.68
Low52 Date	2025-05-08
Low52ch	52.59%
Ma50ch	2.04%
Price vs 200-day SMA	-5.65%
RSI	52.37
RSI Monthly	51.01
RSI Weekly	47.38
Sharpe ratio	1.02x
Sortino ratio	2.06
Total Return	-2.73%
Tr YTD	-16.14
Tr15y	841.18%
Tr1m	1.4%
Tr1w	2.05%
Tr3m	-4.92%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	21
Analyst Count Top	11
Analyst Price Target Top	$32.09
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.07
Earnings EPS Estimate Growth	-36.36
Earnings Revenue Estimate	280,648,128x
Earnings Revenue Estimate Growth	14.87x
Operating Income	$80.9M
Operating Income Growth	-8.44
Operating margin	7.39
Price target	$30.86
Price Target Change	$37.77
Price Target Change Top	$43.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	127,347,376%
Float Percent	74.37%
Shares Insiders	0.58%
Shares Institutions	72.43%
Shares Out	171,235,870
Shares Qo Q	0.79%
Shares Yo Y	2.73%
Short Float	8.62%
Short Ratio	5.87
Short Shares	6.41

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$58.1M
Average Volume	1,996,503.5x
Bv Per Share	7.29
CAPEX	$-9.9M
Ch10y	-18.99
Ch15y	841.2
Ch1m	1.4
Ch1w	2.05
Ch1y	51.25
Ch20y	86.36
Ch3m	-4.92
Ch3y	2.14
Ch5y	6.31
Ch6m	-0.75
Change	-0.71%
Change From Open	-0.13
Close	22.56
Days Gap	-0.58
Depreciation Amortization	11,802,000
Dollar Volume	46,689,283.2
Earnings Date	2026-05-06
Earnings Time	amc
EBIT	$80.9M
EBITDA	$92.7M
EPS	$2.2
F Score	5
FCF	$113.6M
FCF EV Yield	3.74x
FCF Per Share	$0.66
Financing CF	52,276,000
Fiscal Year End	December
Founded	1,993
Graham Number	18.98324
Graham Upside	-15.25
Income Tax	$-260.5M
Investing CF	-112,234,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	23.61
Ma150ch	-5.13%
Ma20	22.07
Ma20ch	1.5%
Net CF	63,592,000
Next Earnings Date	2026-08-05
Open	22.43
Optionable	Yes
P FCF Ratio	33.77
P OCF Ratio	31.06
Position In Range	21.54
Post Close	22.4
Postmarket Change Percent	-0.36
Postmarket Price	$22.32
Ppne	60,926,000
Price Date	2026-05-08
Price EBITDA	$41.37
Ptbv Ratio	3.36
Relative Volume	1.04x
Revenue	1,095,250,000x
SBC By Revenue	5.06x
Share Based Comp	55,453,000
Tax By Revenue	-23.79x
Tr20y	86.36%
Tr6m	-0.75%
Us State	California
Volume	2,084,343
Z Score	6.24

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ACAD pay a dividend?

Capital-return profile for this ticker.

Performance

ACAD stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ACAD?

Insider, institutional, and short-interest positioning.

Institutional ownership

+72.4%

Float: +74.4% of shares outstanding

Insider ownership

+0.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ACAD momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.4

Neutral momentum band

Price vs 200-day MA

-5.6%

50/200-day relationship not available

Beta (5Y)

0.86

Moves roughly with the market

Sharpe ratio

1.02

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ACAD

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ACAD stock rating?

ACADIA Pharmaceuticals Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ACAD analysis?

The full report lives at /stocks/ACAD/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ACAD?

The latest report frames ACAD around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ACAD page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.